The reference standard for the diagnosis will be histology or clinical outcome at the 12 month assessment according to the standard protocol. There will be a centrally pathology review of 10% of the patients (random selection) for quality assurance.
The primary outcome is incremental diagnostic value (sensitively and specificity) of PET/ CT in addition to standard diagnostic work up with CT.
Measurements of cost and secondary outcomes will use a decision analytic model to assess the cost effectiveness of PET/CT in addition to current practice in management of suspected pancreatic cancer as compared with current practice alone.
Sorry there are currently no job vacancies
"The experience and treatment I received at the Royal Liverpool Hospital was so fantastic that I had to tell the people involved with my treatment how marvelous they were, so please would you pass on my thanks and gratitude to Professor Neoptolemos and his team of surgeons, the wonderful doctors and nursing staff" - Anon (Participant in ESPAC-3(v2) trial)
Read more Patient stories